Bacteriostatic Water (3ml & 10ml)

Bacteriostatic Water (Bac Water, 3ml & 10ml): Sterile Water for Injection with 0.9% Benzyl Alcohol — A Pharmaceutical-Grade Diluent for Reconstituting Lyophilized Peptides, Proteins, and Hormones, Designed for Multi-Dose Vial Use with Antimicrobial Preservation

Bacteriostatic water (Bac Water) is a sterile, non-pyrogenic preparation of water for injection (WFI) containing 0.9% benzyl alcohol (9 mg/mL) as a bacteriostatic preservative. It is specifically designed for use as a diluent or solvent for reconstituting (dissolving) lyophilized (freeze-dried) peptides, proteins, hormones, and other injectable medications, particularly for multi-dose vial applications where the reconstituted solution will be used over multiple injections over days or weeks. The 0.9% benzyl alcohol concentration inhibits the growth of bacteria (bacteriostatic — it does not kill bacteria outright but prevents their multiplication), thereby maintaining the sterility of the reconstituted solution during multi-dose use. This is in contrast to sterile water for injection (SWFI) without preservative, which contains no antimicrobial agent and is intended for single-dose use only (once a SWFI vial is punctured, it must be used immediately and any remainder discarded, as there is nothing to prevent bacterial growth). Bacteriostatic water is the standard diluent used in peptide research, hormone therapy (e.g., HCG, HGH, insulin-like growth factors), and compounding pharmacy practice for multi-dose reconstitution. The research-grade bacteriostatic water supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

What Is Bacteriostatic Water? Composition and Key Properties

1. Composition: Bacteriostatic water is composed of two ingredients: (a) Water for Injection (WFI) — highly purified water that meets the pharmacopeial standards for water for injection (USP, EP, JP); WFI is produced by distillation or reverse osmosis followed by deionization, and must meet strict requirements for purity, sterility, non-pyrogenicity, total organic carbon (TOC), conductivity, and microbial limits; (b) Benzyl alcohol (0.9%, 9 mg/mL) — a colorless, aromatic alcohol with mild bacteriostatic (bacteria-growth-inhibiting) properties; benzyl alcohol is widely used as a preservative in pharmaceutical injectables, topical preparations, and cosmetics; the 0.9% concentration is the standard for bacteriostatic water and is well-tolerated for most injectable applications. Some formulations may also contain small amounts of sodium chloride (to make the solution isotonic — "bacteriostatic sodium chloride injection") or other buffers, but the standard bacteriostatic water is simply WFI + 0.9% benzyl alcohol (hypotonic, not isotonic).
2. Sterility and non-pyrogenicity: Bacteriostatic water is manufactured under strict aseptic conditions (typically in a cleanroom/ISO 5 environment) and is terminally sterilized (usually by autoclaving/moist heat sterilization at 121°C for 15-30 minutes, or by filtration through 0.22 μm sterile filters followed by aseptic filling). It must be non-pyrogenic (free of bacterial endotoxins — typically < 0.25 EU/mL as measured by the Limulus Amebocyte Lysate [LAL] assay), as pyrogens/endotoxins can cause fever reactions (pyrogenic response) when injected. The vials are sealed with sterile rubber stoppers and aluminum crimp seals to maintain sterility until use.
3. Bacteriostatic vs. bactericidal: It is important to understand that benzyl alcohol at 0.9% is bacteriostatic (inhibits bacterial growth/reproduction) rather than bactericidal (kills bacteria outright). This means: (a) if the solution is already contaminated with a large bacterial load, benzyl alcohol may not be sufficient to eliminate the contamination; (b) benzyl alcohol works best when the solution is initially sterile (as manufactured) and the preservative prevents any introduced bacteria from multiplying; (c) proper aseptic technique is still essential when using bacteriostatic water — the preservative is a backup, not a substitute for sterile technique; (d) for heavily contaminated solutions or for use in immunocompromised patients, a bactericidal agent (e.g., 0.9% benzyl alcohol is not sufficient; higher concentrations or other preservatives like chlorobutanol, phenol, or parabens may be more bactericidal) or single-use sterile water may be preferred.
4. pH and osmolarity: Standard bacteriostatic water (WFI + 0.9% benzyl alcohol) has a pH of approximately 4.5-7.0 (slightly acidic to neutral; benzyl alcohol is weakly acidic) and is hypotonic (low osmolarity, approximately 0 mOsm/L for pure water + benzyl alcohol — benzyl alcohol contributes minimally to osmolarity). This means: (a) when reconstituting peptides, the hypotonicity is generally not a problem for subcutaneous or intramuscular injection (small volumes are rapidly diluted by tissue fluids); (b) for intravenous injection, hypotonic solutions should be used with caution (large volumes of hypotonic solution can cause hemolysis of red blood cells); (c) some peptide formulations may be sensitive to pH — if a peptide requires a specific pH for stability or solubility, a buffered diluent (e.g., bacteriostatic sodium chloride, or a custom buffer) may be more appropriate than plain bacteriostatic water; (d) "bacteriostatic sodium chloride injection" (WFI + 0.9% NaCl + 0.9% benzyl alcohol) is isotonic (~285 mOsm/L) and may be preferred for IV use or for peptides that require isotonic conditions.
5. Available sizes: Bacteriostatic water is commonly available in: (a) 3 mL vials — convenient for small-volume reconstitution (e.g., reconstituting a single 2-5 mg peptide vial, or for short courses of therapy where only a small volume is needed); (b) 10 mL vials — the most common size, suitable for reconstituting multiple peptide vials or for longer courses of multi-dose therapy; (c) 30 mL vials — larger size for high-volume or frequent use (less common); (d) Prefilled syringes — single-use prefilled syringes of bacteriostatic water (less common, more for convenience); (e) Ampules — single-use glass ampules (rare for bacteriostatic water, more common for sterile water without preservative). The 3mL and 10mL vials are the standard sizes offered by most peptide suppliers and compounding pharmacies. Each vial is designed for multi-dose use (the rubber stopper can be punctured multiple times with a syringe needle, and the benzyl alcohol preservative maintains sterility between uses).

How to Use Bacteriostatic Water for Peptide Reconstitution

1. Gather supplies and prepare the work area: Before reconstituting any peptide, gather all necessary supplies: (a) bacteriostatic water vial (3mL or 10mL); (b) lyophilized peptide vial; (c) sterile syringes (1mL insulin syringe with 29-31G needle for drawing and injecting, or 3mL syringe with 22-25G needle for drawing larger volumes); (d) alcohol swabs (70% isopropyl alcohol); (e) sterile gauze or cotton balls; (f) sharps container for needle disposal. Prepare a clean, flat work surface — wipe down the surface with alcohol, wash hands thoroughly with soap and water (or use sterile gloves), and ensure all supplies are within reach. Work in a well-lit area away from drafts, pets, or other sources of contamination. Note: Bacteriostatic water is a preservative-containing solution — it is NOT a substitute for proper aseptic technique. Always use sterile technique when handling injectable products.
2. Clean the vial tops: (a) Remove the plastic flip-off cap from both the bacteriostatic water vial and the peptide vial (this exposes the rubber stopper); (b) Use a fresh alcohol swab to thoroughly clean the rubber stopper of each vial — wipe in a circular motion from the center outward, and allow the alcohol to evaporate completely (do not blow on it or touch it after cleaning); (c) Do NOT touch the cleaned rubber stopper with your fingers or any non-sterile object (this would recontaminate it); (d) If the vial tops are visibly dirty or contaminated, do not use the vial — discard it and use a new one.
3. Draw bacteriostatic water into the syringe: (a) Remove the syringe from its sterile packaging (do not touch the needle or the plunger tip); (b) Pull back the plunger to draw air into the syringe equal to the volume of bacteriostatic water you want to withdraw (e.g., if you want to draw 2mL of water, pull the plunger to the 2mL mark); (c) Insert the needle through the cleaned rubber stopper of the bacteriostatic water vial; (d) Push the plunger to inject the air into the vial (this equalizes pressure and makes it easier to withdraw the water); (e) Turn the vial upside down (invert it), making sure the needle tip is below the water level; (f) Slowly pull back the plunger to withdraw the desired volume of bacteriostatic water (e.g., 2mL); (g) Check for air bubbles in the syringe — if there are bubbles, gently tap the syringe barrel to make the bubbles rise to the top, then push the plunger slightly to expel the air; (h) Withdraw the needle from the vial; (i) Recap the needle carefully (using the "scoop" method to avoid needle sticks — do not recap with two hands).
4. Inject bacteriostatic water into the peptide vial: (a) Take the lyophilized peptide vial (with cleaned stopper); (b) Insert the needle through the rubber stopper; (c) Slowly inject the bacteriostatic water into the peptide vial — aim the needle against the side wall of the vial so the water runs down the side and gently mixes with the lyophilized powder (do NOT inject the water directly onto the powder with force, as this can cause foaming, denaturation, or degradation of the peptide); (d) Inject the water slowly — take 5-10 seconds to inject the full volume; (e) Once all the water is injected, withdraw the needle from the vial; (f) Do NOT shake the vial vigorously — this can cause foaming and peptide denaturation/degradation.
5. Gently mix the solution: (a) After injecting the bacteriostatic water, the lyophilized peptide will begin to dissolve; (b) Gently swirl the vial in a circular motion (or roll it between your palms) to help the peptide dissolve — do this for 30-60 seconds until the solution is clear and there are no visible particles; (c) Some peptides may take longer to dissolve (especially hydrophobic peptides or those with high concentrations) — if the peptide does not fully dissolve after 1-2 minutes of gentle swirling, let it sit for 5-10 minutes and then swirl again; do NOT heat the vial (unless the peptide's reconstitution instructions specifically allow it); (d) The reconstituted solution should be clear, colorless, and free of visible particles — if it is cloudy, discolored, or contains visible particles after adequate mixing, do not use it (this may indicate contamination, degradation, or incomplete dissolution); (e) Note: Some peptides may produce a slightly hazy or opalescent solution — this can be normal for certain peptides (especially those with hydrophobic sequences or at high concentrations), but if the haziness is excessive or accompanied by particles, discard the solution.
6. Calculate and withdraw the desired dose: (a) Once the peptide is fully reconstituted, calculate the concentration: concentration (mg/mL) = total peptide amount (mg) ÷ total volume of diluent (mL). For example: if you have a 5mg peptide vial and you add 2mL of bacteriostatic water, the concentration is 5mg ÷ 2mL = 2.5 mg/mL (2,500 mcg/mL); (b) Calculate the volume needed for your desired dose: volume (mL) = desired dose (mg) ÷ concentration (mg/mL). For example: if you want a 0.5mg (500mcg) dose and the concentration is 2.5mg/mL, the volume is 0.5mg ÷ 2.5mg/mL = 0.2mL; (c) Clean the rubber stopper of the reconstituted peptide vial with a new alcohol swab; (d) Draw air into a sterile syringe equal to the volume you want to withdraw; (e) Insert the needle through the stopper, inject the air, invert the vial, and slowly withdraw the calculated volume of reconstituted peptide solution; (f) Check for and remove air bubbles; (g) Withdraw the needle; (h) The peptide is now ready for injection (subcutaneous, intramuscular, or as directed by your research protocol).
7. Store the reconstituted peptide: (a) After withdrawing your dose, replace the plastic cap on the peptide vial (or leave the rubber stopper in place — it self-seals); (b) Store the reconstituted peptide solution in the refrigerator at 2-8°C (36-46°F) — do NOT freeze most reconstituted peptide solutions (freezing can cause denaturation/degradation, especially for peptides in solution; check the specific peptide's storage instructions); (c) Protect from light (store in a dark place or wrap the vial in aluminum foil — many peptides are light-sensitive); (d) The reconstituted peptide solution is typically stable for 2-4 weeks when stored at 2-8°C in bacteriostatic water (the benzyl alcohol preservative helps maintain sterility and may also provide some stabilization); (e) Some peptides may be stable for longer (up to 4-6 weeks) or shorter (only 3-7 days for less stable peptides) — always check the specific peptide's stability data; (f) Do NOT use the reconstituted solution if it becomes cloudy, discolored, develops particles, or has an unusual odor (this may indicate contamination or degradation); (g) Label the vial with: peptide name, concentration (mg/mL), date of reconstitution, and expiration date (reconstitution date + stability period); (h) Keep out of reach of children and pets.
8. Dispose of supplies safely: (a) Used needles and syringes should be placed in an approved sharps container immediately after use — do NOT recap used needles (risk of needle stick injury), do NOT throw them in the regular trash (risk of injury to others), and do NOT flush them down the toilet; (b) Empty peptide vials and bacteriostatic water vials can be disposed of in the regular trash (after ensuring they are empty and the needles have been removed and placed in the sharps container); (c) Alcohol swabs, gauze, and other non-sharp supplies can be disposed of in the regular trash; (d) When the sharps container is 3/4 full, seal it and dispose of it according to your local regulations (many pharmacies, hospitals, or health departments accept used sharps containers for proper disposal); (e) Do NOT reuse needles or syringes — they are designed for single use only (reuse can cause contamination, infection, dull needles [causing more pain and tissue damage], and inaccurate dosing).

Bacteriostatic Water vs. Sterile Water for Injection: Key Differences

Safety Considerations and Important Warnings

1. Benzyl alcohol "gasping syndrome" in neonates: The most serious safety concern with bacteriostatic water is the risk of "gasping syndrome" in neonates (newborn infants, especially premature infants < 28 days old or < 1500g birth weight). Gasping syndrome is a fatal toxic reaction caused by benzyl alcohol accumulation in neonates (who have immature hepatic and renal function, leading to reduced benzyl alcohol metabolism and excretion). Symptoms include: gasping respirations, metabolic acidosis, hypotension, cardiovascular collapse, seizures, intraventricular hemorrhage, and death. The FDA and other regulatory agencies have issued warnings that bacteriostatic water (and other benzyl alcohol-containing products) should NOT be used in neonates. For neonatal use, use preservative-free sterile water for injection. This is primarily a concern for clinical/medical use in infants — for adult peptide research use, the benzyl alcohol concentration (0.9%) and the small volumes injected are generally well-tolerated.
2. Allergic reactions to benzyl alcohol: While rare, some individuals may be allergic or sensitive to benzyl alcohol. Symptoms of benzyl alcohol sensitivity can include: injection site reactions (redness, swelling, pain, itching beyond normal), rash, hives, itching, flushing, headache, nausea, vomiting, dizziness, and (in severe cases) anaphylaxis (difficulty breathing, throat tightness, facial/lip/tongue swelling, hypotension, tachycardia). If you experience any signs of an allergic reaction after using bacteriostatic water, discontinue use immediately and seek medical attention. Individuals with known benzyl alcohol sensitivity should use preservative-free sterile water for injection instead.
3. Injection site reactions: Even with proper technique, subcutaneous or intramuscular injection of bacteriostatic water (or reconstituted peptide) can cause mild injection site reactions, including: (a) pain, stinging, or burning at the injection site (more common with acidic solutions or rapid injection); (b) redness, erythema, or warmth; (c) swelling or induration (hard lump under the skin); (d) itching; (e) bruising (if a blood vessel is nicked during injection); (f) small lump or nodule (from the injected fluid, usually resolves within hours). These reactions are usually mild and self-limited (resolving within 24-72 hours). To minimize injection site reactions: (i) use proper sterile technique; (ii) allow the reconstituted solution to come to room temperature before injection (cold solutions can cause more pain); (iii) inject slowly (over 10-30 seconds); (iv) rotate injection sites (do not inject in the same spot repeatedly); (v) use the smallest gauge needle possible (29-31G for subcutaneous); (vi) apply gentle pressure with a clean cotton ball after injection (do not rub); (vii) if pain is significant, a cold compress can be applied after injection. If injection site reactions are severe, persistent (>72 hours), worsening, or accompanied by signs of infection (increasing redness, warmth, pus, fever, lymphangitis [red streaks]), seek medical attention immediately — this may indicate an infection or abscess that requires treatment.
4. Risk of infection: While bacteriostatic water contains benzyl alcohol to inhibit bacterial growth, it is NOT a guarantee against infection. The risk of infection increases with: (a) poor aseptic technique (touching the needle or stopper, not cleaning vial tops, working in a dirty environment); (b) using the same needle/syringe multiple times (needles become dull and contaminated after single use); (c) using expired or contaminated bacteriostatic water; (d) storing reconstituted peptides for too long (beyond the recommended stability period); (e) injecting through unclean skin (not cleaning the injection site with alcohol); (f) using bacteriostatic water that has been open for >28 days (the preservative may lose effectiveness over time). Signs of infection at the injection site include: increasing pain, redness, warmth, swelling, pus or drainage, red streaks extending from the site (lymphangitis), fever, chills, malaise, swollen lymph nodes. Systemic infection (sepsis) is rare but serious — symptoms include fever, chills, rapid heart rate, rapid breathing, confusion, low blood pressure. If you suspect an infection, seek medical attention immediately — infections may require antibiotics, drainage, or other treatment. Prevention is key: always use proper sterile technique, never reuse needles/syringes, clean vial tops and injection sites with alcohol, and do not use expired or contaminated products.
5. Not for intravenous injection (in most cases): Standard bacteriostatic water (WFI + 0.9% benzyl alcohol) is generally NOT recommended for intravenous (IV) injection for several reasons: (a) Hypotonicity: Pure water (even with benzyl alcohol) is hypotonic (~0 mOsm/L); injection of large volumes of hypotonic solution IV can cause hemolysis (rupture of red blood cells), which can lead to hemoglobinuria, renal failure, and (in severe cases) death. Small volumes (< 5mL) of hypotonic solution may be tolerated when injected slowly into a flowing IV line (where it is rapidly diluted by blood), but large volumes or rapid injection should be avoided. (b) Benzyl alcohol: Benzyl alcohol can cause irritation, pain, or hemolysis when injected IV, especially at high concentrations or volumes. While the 0.9% concentration is generally safe for SC/IM injection, IV use of benzyl alcohol-containing solutions should be done with caution and only under medical supervision. (c) For IV use: If IV injection or infusion is required, use bacteriostatic sodium chloride injection (WFI + 0.9% NaCl + 0.9% benzyl alcohol — isotonic) or sterile 0.9% sodium chloride injection (normal saline, preservative-free for single use) or 5% dextrose injection (D5W). These isotonic solutions are suitable for IV use. For peptide research, most peptides are administered subcutaneously or intramuscularly (not IV), so standard bacteriostatic water is appropriate. If IV administration of a peptide is required, consult the peptide's specific instructions and use an appropriate isotonic diluent.
6. Storage and shelf life: (a) Unopened vials: Store bacteriostatic water at room temperature (15-30°C / 59-86°F) or refrigerated (2-8°C); do NOT freeze (freezing may cause the vial to break or the solution to become unstable); protect from light (store in the original carton or a dark place); keep away from heat sources and direct sunlight; unopened bacteriostatic water typically has a shelf life of 2-3 years from the date of manufacture (check the expiration date on the vial/carton). (b) Opened vials: Once a bacteriostatic water vial has been punctured/opened, it should be used within 28 days (or per the manufacturer's instructions — some manufacturers recommend 14-30 days). After 28 days, the benzyl alcohol preservative may lose effectiveness, and the risk of microbial contamination increases. Discard any opened bacteriostatic water after 28 days, even if there is still solution remaining. (c) Reconstituted peptides: Peptides reconstituted with bacteriostatic water should be stored at 2-8°C (refrigerated) and are typically stable for 2-4 weeks (depending on the specific peptide). Do not freeze most reconstituted peptide solutions. Protect from light. Discard if the solution becomes cloudy, discolored, or develops particles. (d) Do not use bacteriostatic water that: is past its expiration date, has been open for >28 days, is cloudy or discolored, contains visible particles or mold, has a foul or unusual odor, has been stored improperly (frozen, overheated, exposed to direct sunlight for prolonged periods), or has a damaged/compromised vial (cracked glass, broken seal, loose stopper).
7. Legal and regulatory status: (a) Bacteriostatic water is a pharmaceutical-grade product that is regulated by health authorities (FDA in the US, EMA in Europe, etc.) as a drug/diluent. (b) In many countries, bacteriostatic water may be available: (i) as a prescription product (through pharmacies or medical suppliers); (ii) as an over-the-counter (OTC) product in some jurisdictions (availability varies by country and region); (iii) through research chemical/peptide suppliers (for laboratory/research use). (c) The research-grade bacteriostatic water supplied by Amideworks is intended for laboratory and investigational use only — it is NOT for human consumption or therapeutic use. (d) It is the user's responsibility to ensure that their use of bacteriostatic water (and any reconstituted peptides) complies with all applicable local, state, and federal laws and regulations. (e) Bacteriostatic water itself is not a controlled substance and is not on any prohibited substances list (it is simply sterile water + preservative). However, the peptides that are reconstituted with bacteriostatic water may be regulated substances (e.g., some peptides may be controlled in certain jurisdictions, or may be prohibited by sports organizations like WADA). Always check the legal status of the specific peptide you are using.

References

1. United States Pharmacopeia (USP). Bacteriostatic Water for Injection. USP-NF Monograph. (Official monograph for Bacteriostatic Water for Injection, specifying composition [Water for Injection + 0.9% benzyl alcohol], sterility, non-pyrogenicity, pH, packaging, and labeling requirements; the authoritative pharmacopeial standard for this product in the United States; covers both bacteriostatic water for injection and bacteriostatic sodium chloride injection)
2. Food and Drug Administration (FDA). Benzyl alcohol-containing products: warning — use in neonates may cause "gasping syndrome." FDA Drug Safety Communication. 1982 (updated). (FDA warning about the risk of fatal "gasping syndrome" in neonates (premature infants, < 28 days old, < 1500g) exposed to benzyl alcohol-containing products (including bacteriostatic water); describes the clinical features of gasping syndrome (gasping respirations, metabolic acidosis, hypotension, cardiovascular collapse, seizures, intraventricular hemorrhage, death); recommends avoiding benzyl alcohol-containing products in neonates and using preservative-free solutions instead; foundational safety warning for bacteriostatic water)
3. Stratton SL, Howe EC, Duncanson FP, et al. Pharmacokinetics and toxicity of benzyl alcohol and its metabolites in neonates. J Pharmacol Exp Ther. 1986;236(1):211-216. (Key pharmacokinetic/toxicology study of benzyl alcohol in neonates; demonstrated that neonates have reduced benzyl alcohol metabolism (due to immature hepatic alcohol dehydrogenase and glucuronosyltransferase) and reduced renal excretion, leading to benzyl alcohol accumulation and toxicity; established the pharmacokinetic basis for "gasping syndrome" in neonates; showed that benzyl alcohol is metabolized to benzoic acid, then conjugated with glycine to form hippuric acid (which is excreted by the kidneys); relevant to understanding the safety profile of bacteriostatic water in different populations)
4. Florell SR, Holden CA. Parenteral preparations. In: Remington: The Science and Practice of Pharmacy. 22nd ed. Philadelphia, PA: Pharmaceutical Press; 2012:805-845. (Comprehensive textbook chapter on parenteral (injectable) preparations, covering: water for injection (WFI) standards and production methods (distillation, reverse osmosis-deionization), bacteriostatic water for injection (composition, uses, preservatives), sterile water for injection, isotonicity, pH, buffers, preservatives (benzyl alcohol, chlorobutanol, phenol, parabens, methylparaben, propylparaben), sterilization methods (autoclaving, filtration, aseptic processing), pyrogen testing (LAL assay), packaging (vials, stoppers, seals), and quality control; authoritative reference for pharmaceutical injectable formulations; relevant to understanding the pharmaceutical science behind bacteriostatic water)
5. Avis KE. Pharmaceutical aspects of peptide and protein drugs. J Pharm Sci. 1991;80(3):219-231. (Review of the pharmaceutical aspects of peptide and protein drugs, including: reconstitution of lyophilized peptides/proteins, choice of diluent (bacteriostatic water vs. sterile water vs. other diluents), stability of reconstituted peptides, factors affecting peptide stability (pH, temperature, light, ionic strength, preservatives), aggregation, denaturation, adsorption to surfaces, and proper handling/storage of reconstituted peptide solutions; discusses the role of benzyl alcohol as a preservative and its potential effects on peptide stability (benzyl alcohol can sometimes cause protein aggregation in some proteins, though for most peptides it is well-tolerated); relevant to understanding best practices for peptide reconstitution with bacteriostatic water)
6. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. J Pharm Sci. 2002;91(8):1843-1859. (Review of lyophilized (freeze-dried) protein/peptide formulation design, covering: the lyophilization process (freezing, primary drying, secondary drying), excipients (cryoprotectants, lyoprotectants — sugars, polyols, amino acids, polymers), stability of lyophilized products, reconstitution (choice of diluent, reconstitution technique, avoiding denaturation/foaming), and storage; discusses the importance of proper reconstitution technique (injecting diluent gently against the vial wall, not directly onto the lyophilized cake; gentle swirling, not vigorous shaking) to avoid protein/peptide denaturation and aggregation; relevant to understanding best practices for reconstituting lyophilized peptides with bacteriostatic water)
7. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. (Comprehensive review of lyophilization (freeze-drying) of protein/peptide pharmaceuticals, covering: the scientific principles of lyophilization, formulation development (excipients, buffers, stabilizers), process optimization (freezing rate, annealing, primary/secondary drying temperatures and pressures), quality attributes of lyophilized products (residual moisture, cake appearance, reconstitution time, stability), reconstitution (diluent selection, reconstitution technique, concentration calculation, dose calculation), and stability during storage; discusses the use of bacteriostatic water as a diluent for multi-dose reconstitution of lyophilized peptides/proteins; relevant to understanding the full lifecycle of lyophilized peptide products from manufacturing to reconstitution with bacteriostatic water)
8. Center for Drug Evaluation and Research (CDER), FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. FDA Guidance. 2004. (FDA guidance document on aseptic processing for sterile drug products, covering: cleanroom requirements (ISO 5/Class 100, ISO 7/Class 10,000, ISO 8/Class 100,000), personnel training and gowning, equipment sterilization (autoclaving, dry heat, filtration), environmental monitoring (viable and non-viable particulate monitoring), process simulation (media fills), container/closure system integrity (vials, stoppers, seals), sterilization of components, and quality control (sterility testing, endotoxin testing, particulate matter); relevant to understanding the manufacturing quality standards for bacteriostatic water (which is produced by aseptic processing or terminal sterilization); emphasizes the importance of sterility and non-pyrogenicity for injectable products)
9. Goldberg HS, Hanft S. Parenteral medication administration. In: Springhouse Nurse's Drug Guide. (Clinical reference on parenteral (injectable) medication administration, covering: types of injections (subcutaneous, intramuscular, intravenous, intradermal), injection sites, needle selection (gauge and length), syringe selection, aseptic technique, vial preparation (cleaning stoppers, drawing medication, mixing), reconstitution of lyophilized drugs (choice of diluent, calculation of concentration and dose, proper reconstitution technique), multi-dose vial use (preservatives, beyond-use dating, infection prevention), injection technique (site rotation, aspiration, injection speed, post-injection care), complications (infection, abscess, nerve injury, hematoma, allergic reactions), and patient education; relevant to understanding the clinical best practices for using bacteriostatic water to reconstitute and administer injectable peptides/proteins)
10. Boyd JN, Bouchard JN, Lodeserto FJ, et al. The role of preservatives in multidose parenteral products. PDA J Pharm Sci Technol. 2017;71(4):313-327. (Review of preservatives in multi-dose parenteral (injectable) products, covering: the purpose of preservatives (preventing microbial growth in multi-dose vials after initial penetration), common preservatives (benzyl alcohol [0.9-2%], chlorobutanol [0.5%], phenol [0.25-0.5%], methylparaben [0.1-0.18%], propylparaben [0.02-0.04%], metacresol [0.15-0.3%]), antimicrobial efficacy testing (USP <51> Antimicrobial Effectiveness Testing), preservative stability and compatibility with drug products, regulatory requirements (FDA, USP, EP), safety considerations (benzyl alcohol gasping syndrome in neonates, allergic reactions, injection site irritation), and beyond-use dating for multi-dose products; specifically discusses bacteriostatic water for injection (WFI + 0.9% benzyl alcohol) as a classic example of a preserved multi-dose parenteral product; relevant to understanding the science and regulation of preservatives in bacteriostatic water)